Financials
Financial year 2025
Worth noting
- A loss two years in a row.
Gross margin
€ -528,205
▼ 135% vs 2024
Profit
Caution€ -2.5 million
▼ 38% vs 2024
Debts
Low€ 315,766
▲ 287% vs 2024
Tanai Therapeutics from Gent, company number BE1002228546, closed financial year 2025 with a result of € -2.5 million after tax. For that financial year Tanai Therapeutics recorded a gross margin of € -528,205 and equity of € 3.6 million. Compared with financial year 2024, the result moved from € -1.8 million to € -2.5 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 22, 2026.
What happened at Tanai Therapeutics?
What happened at Tanai Therapeutics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- PROsVenture BV stepped down as director. NBB
- Johanne Hendrikke Ellenbroek stepped down as director. NBB
- Carla Maria Coleta Snoeck stepped down as director. NBB
- Shelley Jane Margetson stepped down as director. NBB
- QBic Venture Partners III NV stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.5 million. Source: NBB ↗
- PROsVenture BV became a director. NBB
- Johanne Hendrikke Ellenbroek became a director. NBB
In short
From € 1.8 million loss in 2024 to € 2.5 million loss in 2025.
A new publication or filing at Tanai Therapeutics? We notify you, reason included.
Follow Tanai TherapeuticsNeed more data?
History
Every financial year, as far back as the National Bank goes.
Buffer
How long does the company survive without income?
Credit limit
Indicative credit limit, computed from the real figures.
Alerts
News about who you follow, reason included.
Then €29.99/mo excl. VAT, cancel monthly. No credit card to try; the AI assistant is not included, or only in a very limited form, during the trial month. Sign up now and you’ll be invited first.
Management
Directors
According to the 2025 annual accounts
Carla Maria Coleta Snoeck
Director
since 2023 · until 2029
since 2024 · until 2031
Johanne Hendrikke Ellenbroek
Director
since 2024 · until 2030
Shelley Jane Margetson
Director
since 2023 · until 2029
Director · represented by Sara Vandenwijngaert
Also active at: RheaVita, VoxelSensors, AnimAb +7 more
since 2023 · until 2029
Establishments
Establishment units
Physical locations of this company
Pieter van Reysschootlaan 2 box 104
9051 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 13 companies are registered at this address.
CD-Vastgoed
€ 437,585 gross margin · 2025
V-BIO PARTNERS 1
€ -2,244 gross margin · 2025
V-BIO MANAGEMENT 1
€ 822,886 revenue · 2025
V-Bio Fund 1
€ -903,749 gross margin · 2025
V-Bio Co-Invest 1-1
€ -16,692 gross margin · 2025
+8 more
Website
Technologies
Hosting & Email
Email provider
Self-hosted
Hosting
COMBELL-AS, BE
Website info
Features
Security
Details
- Company number
- 1002.228.546
- VAT number
- BE 1002.228.546
- Registered office
- Pieter van Reysschootlaan 2 bus 104, 9051 Gent
- Names & denominations
- Tanai Therapeutics
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 13 November 2023
- Peppol
- Active · Active since 2 Jan 2026
- Contact
- dokterlagast.be
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied